Catalyst's Firdapse (amifampridine) Receives FDA's Approval for Lambert-Eaton Myasthenic Syndrome
Shots:
- The approval is based on two clinical trial results assessing Firdapse vs PBO in 64 patients with Lambert-Eaton Myasthenic Syndrome
- The study measured Quantitative Myasthenia Gravis score (assessing muscle weakness) and demonstrated overall impression having effective results vs PBO
- Firdapse (amifampridine) is an EU approved drug in Dec 2009- indicated for symptomatic treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) and has also received FDA’s PT- BT & ODD
Ref: Catalyst | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com